共 55 筆專利技術
短胜肽及其組合物用於治療或/及預防骨骼肌萎縮症或與其相關疾病之用途
Sarcopenia is an aging associated involving skeletal muscle atrophy and reduction in muscle strength; and there are no pharmaceutical interventions available so far. Moreover, conditions like hyperglycaemia are known to further intensify muscle degradation. Therefore, novel strategies to attenuate skeletal muscle loss are essential to enhance muscle function and thereby to improve the quality of life in diabetic individuals. In this study we have investigated the efficiency of a soybean peptide fraction APPH and a short peptide from PP622 named DI-10 for their cytoprotective effects in skeletal muscle cells. PP622 and DI-10 treatment in C2C12 cells showed dose dependent activation of Akt/mtor signalling pathway that is involved in skeletal myogenesis. According to Western blotting analysis, PP622 and DI-10 induced the phosphorylation of Akt, mTOR proteins and induced myogenic differentiation of C2C12 myoblasts in a differentiation medium. The phosphorylation myogenic transcription factor Foxo3A was also found to be increased in the cells treated with PP622 and DI-10. In addition, reduction in cell viability caused by high glucose was also found to be reduced when treated with different doses of high glucose in a dose dependent manner. Moreover, number of myotybules in a differentiation medium reduced upon high glucose challenge, but treatment with PP622 increased the number of differentiated myotubules. Further, the phosphorylations of AMPK and mitochondrial-related transcription factors such as PGC-1α were suppressed upon high glucose challenge but PP622 and DI-10 treatment restored the protein levels. We demonstrate for the first time that a specific potato peptide has a therapeutic effect against sarcopenia. In addition, DI-10 and PP622 improved the myogenic differentiation and their mitochondrial biogenesis and further improved mygenic protein and inhibited muscle protein degradation in C212 cells challenged under high glucose condition.
肌少症是與老化相關的疾病，涉及骨骼肌萎縮和肌力減少；目前尚無有效的藥物治療方法。此外，像是高血糖等情況已知會進一步加劇肌肉退化。因此，開發新的策略來減緩骨骼肌損失對於提高肌肉功能並改善糖尿病患者的生活品質至關重要。在本研究中，我們探討了大豆肽分子APPH和PP622中短肽DI-10在骨骼肌細胞中的細胞保護效應。PP622和DI-10在C2C12細胞中的處理顯示出劑量依賴性地激活了涉及骨骼肌生成的Akt/mTOR信號通路。根據Western blot分析，PP622和DI-10誘導了Akt、mTOR蛋白的磷酸化，並在分化培養基中促進了C2C12肌母細胞的肌源性分化。在處理過PP622和DI-10的細胞中，我們還發現肌源性轉錄因子Foxo3A的磷酸化水準也有所增加。此外，在高糖挑戰下，細胞活力的下降被發現隨著不同劑量的高糖處理呈劑量依賴性減少。更重要的是，在分化培養基中，經高糖挑戰後，肌管數量減少，但PP622處理後，分化肌管的數量有所增加。此外，AMPK的磷酸化及與線粒體相關的轉錄因子如PGC-1α在高糖挑戰下被抑制，但PP622和DI-10的處理恢復了這些蛋白質的水平。我們首次證明了特定的馬鈴薯肽對抗肌少症的治療效果。此外，DI-10和PP622改善了肌源性分化、線粒體生物生成，並進一步改善了肌源性蛋白質，抑制了在高糖環境下C2C12細胞中的肌肉蛋白降解。
閱讀詳細資料北蟲草黑豆發酵水萃物用於抗疲勞及提升運動效果之用途
北蟲草(Cordyceps militaris)是種珍貴藥用菇類，富含多種機能性成份，包括腺苷和蟲草素等。本專利技術主要將北蟲草接種於豆類基質，進行固態培養，所得固態發酵產品以水萃而得萃取物，並利用ICR小鼠模型進行抗疲勞效果評估。
動物實驗分為控制組(去離子水)、正控制組(長庚生物科技北蟲草菌絲體膠囊)及萃取物實驗組經28天餵食，萃取物分為高(1 g/kg)、中(0.5 g/kg)和低(0.25 g/kg)劑量3組，利用前肢抓力及游泳試驗，並分析小鼠血液中抗疲勞相關生化參數，測試北蟲草豆類萃取物是否具有抗疲勞效果。
研究結果顯示，在前肢抓力試驗方面，中(122.4 KgF)和高(133.6 KgF)萃取物劑量組顯著優於控制組(89.6 KgF)；另游泳試驗方面，高劑量組(870.2 s)顯著優於控制組(484.0 s)。此外，高劑量組可降低尿素氮、肌酸激酶、乳酸和乳酸去氫酶，另可透過調節肝醣及血糖提供能量來源。綜上可知北蟲草豆類固態發酵培養萃取物高劑量組(1 g/kg)具有抗疲勞效果。
閱讀詳細資料